SCHEMBL15526486

SCHEMBL15526486

Cc1cc(C(=O)O)ccc1-c1cnc(C)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADH5 P11766 3/20 0.48
EIF4E P06730 1/20 0.46
SCN9A Q15858 1/20 0.44
RARB P10826 1/20 0.44
MAP4K4 O95819 3/20 0.43
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
TNKS2 Q9H2K2 1/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMO O15229 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LDHA P00338 1/20 0.39
NAPRT Q6XQN6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16651019 0.89 ADH5 (0.48) ADH5EIF4ESCN9ARARBMAP4K4
SCHEMBL15526469 0.84 SCN9A (0.53) ADH5SCN9A
SCHEMBL16650261 0.82 SCN9A (0.42) SCN9AROCK2ROCK1
SCHEMBL20794151 0.76 ADH5 (0.50) ADH5SCN9ARARB
SCHEMBL1131951 0.75 RARB (0.57) ADH5EIF4ERARBMAP4K4TNKS2
SCHEMBL18708503 0.75 NPC1 (0.57) RARBMAP4K4TSHR
SCHEMBL11507830 0.74 RARB (0.63) ADH5RARBMAP4K4AKR1C3AKR1C2
SCHEMBL1105964 0.74 HCAR2 (0.47) TSHRKDM4EALDH1A1NAPRT
SCHEMBL13601689 0.74 TTR (0.50) EIF4EMAP4K4AKR1C3AKR1C2TNKS2
SCHEMBL68014 0.74 ALDH1A1 (0.57) ADH5RARBTSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844252-B1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-11-30 EP disclosed
US-9353101-B2 Cyclic amine substituted heterocyclic CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-31 US disclosed
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-23 US disclosed
EP-2844252-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-03-11 EP disclosed
WO-2013165854-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS CETP, APOB, MTTP ADH5 1825/4885EIF4E 3511/4885SCN9A 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.